Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology

Current Rheumatology Reports

Volumn 10, Issue 2, 2008, Pages 156-163

  Syed, Reema H ^b   Gilliam, Brooke E ^b   Moore, Terry L ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IMMUNOGLOBULIN CLASS;

ANTIBODY DETECTION; CHILD; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; JOINT INJURY; JUVENILE RHEUMATOID ARTHRITIS; LATEX AGGLUTINATION TEST; PATIENT MONITORING; PHYSICAL DISABILITY; POLYARTHRITIS; REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; CLASSIFICATION; IMMUNOLOGY;

ARTHRITIS, JUVENILE RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHILD; HUMANS; IMMUNOGLOBULIN ISOTYPES; PEPTIDES, CYCLIC; RHEUMATOID FACTOR;

EID: 44949156486     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0027-4     Document Type: Review

References (50)

1. Cassidy JT, Petty RE, eds: Chronic arthritis in children. In Textbook of Pediatric Rheumatology. Philadelphia: Elsevier Saunders; 2005:206-260.
2. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis. J Rheumatol 1998, 25:1991-1994.
3. Ravelli A, Martini A: Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003, 21(5 Suppl 31):S89-S93.
4. Berglin E, Johansson T, Sundin U, et al.: Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453-458.
5. Ates A, Kinikli G, Turgay M, et al.: Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 2007, 26:538-545.
6. Ferreira RA, Ferriani VP, Sopelete MC, et al.: Immunoglobulin E-rheumatoid factor in juvenile rheumatoid arthritis. Rev Hosp Clin Fac Med Sao Paulo 2002, 57:209-216.
7. Moore TL, Dorner RW: Rheumatoid factors. Clin Biochem 1993, 26:75-84.
8. Walker SM, McCurdy DK, Shaham B, et al.: High prevalence of IgA rheumatoid factor in severe polyarticular-onset juvenile rheumatoid arthritis, but not in systemic-onset or pauciarticular-onset disease. Arthritis Rheum 1990, 33:199-204.
9. Walker SM, Shaham B, McCurdy DK, et al.: Prevalence and concentration of IgM rheumatoid factor in polyarticular onset disease as compared to systemic or pauciarticular onset disease in active juvenile rheumatoid arthritis as measured by ELISA. J Rheumatol 1990, 17:936-940.
10. Saulsbury FT: Prevalence of IgM, IgA and IgG rheumatoid factors in juvenile rheumatoid arthritis. Clin Exp Rheumatol 1990, 8:513-517.
11. Jarvis JN, Pousak T, Krenz M: Detection of IgM rheumatoid factors by enzyme-linked immunosorbent assay in children with juvenile rheumatoid arthritis: correlation with articular disease and laboratory abnormalities. Pediatrics 1992, 90:945-949.
12. Aggarwal A, Dabadghao S, Naik S, Misra R: Serum IgM rheumatoid factor by enzyme-linked immunosorbent assay (ELISA) delineates a subset of patients with deforming joint disease in seronegative juvenile rheumatoid arthritis. Rheumatol Int 1994, 14:135-138.
13. Varbanova BB, Baleva M, Nikolov K, Mihailova D: Prevalence of IgM-, IgA- and IgG-rheumatoid factors in seronegative polyarticular disease compared to pauciarticular disease in juvenile chronic arthritis as measured by ELISA. Adv Exp Med Biol 1999, 455:61-68.
14. Bharadwaj A, Aggarwal A, Misra R: Clinical relevance of IgA rheumatoid factor (RF) in children with juvenile rheumatoid arthritis. Rheumatol Int 1999, 19:47-49.
15. Bhardwaj A, Aggarwal A, Agarwal V, Misra A: Role of IgM and IgA rheumatoid factors in complement activation in patients with juvenile rheumatoid arthritis. Indian J Med Res 2000, 111:103-109.
16. Ferreira RA, Silva CH, Silva DA, et al.: Is measurement of IgM and IgA rheumatoid factors (RF) in juvenile rheumatoid arthritis clinically useful? Rheumatol Int 2007, 27:345-349.
17. Gilliam BE, Low JM, Chauhan AK, Moore TL: Biomarkers associated with joint damage in juvenile idiopathic arthritis. Arthritis Rheum 2006, 54:S697.
18. Gilliam BE, Chauhan AK, Low JM, Moore TL: Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol 2008, In press.
19. Jónsson T, Steinsson K, Jónsson H, et al.: Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity of rheumatoid arthritis. Rheumatol Int 1998, 18:119-122.
20. Nienhuis RL, Mandema E: A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 1964, 23:302-305.
21. Young BJ, Mallya RK, Leslie RD, et al.: Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979, 2:97-99.
22. Sebbag M, Simon M, Vincent C, et al.: The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995, 95:2672-2679.
23. Simon M, Girbal E, Sebbag M, et al.: The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993, 92:1387-1393.
24. Simon M, Vincent C, Haftek M, et al.: The rheumatoid arthritis-associated autoantibodies to filaggrin label the fibrous matrix of the cornified cells but not the profilaggrin-containing keratohyalin granules in human epidermis. Clin Exp Immunol 1995, 100:90-98.
25. Schellekens GA, de Jong BA, van den Hoogen FH, et al.: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
26. Schellekens GA, Visser H, de Jong BA, et al.: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163.
27. Kroot EJ, de Jong BA, van Leeuwen MA, et al.: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831-1835.
28. van Jaarsveld CH, ter Borg EJ, Jacobs JW, et al.: The prognostic value of the antiperinuclear factor, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999, 17:689-697.
29. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al.: The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001, 166:4177-4184.
30. Menard HA, Lapointe E, Rochdi MD, Zhou ZJ: Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000, 2:429-432.
31. Baeten D, Peene I, Union A, et al.: Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001, 44:2255-2262.
32. Vossenaar ER, Nijenhuis S, Helsen MM, et al.: Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003, 48:2489-2500.
33. Hill JA, Wehrli B, Jevnikar AM, et al.: Citrullinated fibrinogen induces arthritis in HLA-DRB1*0401 transgenic mice. Arthritis Rheum 2003, 48:S348.
34. Nesher G, Moore TL, Gristanti MW, et al.: Antiperinuclear factor in juvenile rheumatoid arthritis. Ann Rheum Dis 1992, 51:350-352.
35. Gabay C, Prieur AM, Meyer O: Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1993, 52:785-789.
36. Hromadnikova I, Stechova K, Pavla V, et al.: Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Autoimmunity 2002, 35:397-401.
37. Avcin T, Cimaz R, Falcini F, et al.: Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608-611.
38. van Rossum M, van Soesbergen R, de Kort S, et al.: Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003, 30:825-828.
39. Kasapcopur O, Altun S, Aslan M, et al.: Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1687-1689.
40. Low JM, Chauhan AK, Kietz DA, et al.: Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004, 31:1829-1833.
41. Kwok JS, Hui KH, Lee TL, et al.: Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005, 34:359-366.
42. Machado SH, von Mühlen CA, Brenol JC, et al.: The prevalence of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. J Pediatr (Rio J) 2005, 81:491-494.
43. Brunner J, Sitzmann FC: Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Mod Rheumatol 2006, 16:372-375.
44. Brunner J, Sitzmann FC: The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2006, 24:449-451.
45. Dewint P, Hoffman IE, Rogge S, et al.: Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2006, 45:204-208.
46. Hall PJ, Burman SJ, Laurent MR, et al.: Genetic susceptibility to early onset pauciarticular juvenile chronic arthritis: a study of HLA and complement markers in 158 British patients. Ann Rheum Dis 1986, 45:464-474.
47. Ferucci ED, Majka DS, Parrish LA, et al.: Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005, 52:239-246.
48. Syed RH, Gilliam BE, Moore TL: Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2008, In press.
49. Low JM, Chauhan AK, Moore TL: Abnormal kappa: lambda light chain ratio in circulating immune complexes as a marker for B cell activity in juvenile idiopathic arthritis. Scand J Immunol 2007, 65:76-83.
50. Vieira LM, d'Orse E, Pereira IA, et al.: A comparison study of second and third generation anti-cyclic citrullinated peptide antibody ELISAs. Arthritis Rheum 2007, 56:S724.